Clinical Trials Logo

Bioequivalency clinical trials

View clinical trials related to Bioequivalency.

Filter by:
  • None
  • Page 1

NCT ID: NCT05665283 Completed - Bioequivalency Clinical Trials

A Single Dose BE Study of X-396 in Healthy Volunteers Under Fasted Conditions

Start date: November 29, 2022
Phase: Phase 1
Study type: Interventional

This is an open-label, Phase I single dose 2-part, crossover bioequivalence study under fasted conditions. The trial is designed to evaluate the pharmacokinetic parameters between single doses of 100mg ensartinib capsules manufactured by two different processes.

NCT ID: NCT01229280 Unknown status - Bioequivalency Clinical Trials

Single Dose Bioequivalence Study of Darifenacin Tablets 7.5 mg in Fed Healthy Volunteers.

Start date: December 2010
Phase: Phase 1
Study type: Interventional

The proposed study was designed as a randomized two-sequence, two period crossover trial to assess the bioequivalence, pharmacokinetic profiling and safety of a brand generic formulation of darifenacin [Darisec(R) 7.5 mg] vs. the innovator [Enablex(R)7.5 mg]in healthy volunteers in postprandial state.

NCT ID: NCT01227811 Unknown status - Bioequivalency Clinical Trials

Single Dose Two-periods Crossover Bioequivalence Study of Darifenacin Tablets in Healthy Volunteers.

Start date: November 2010
Phase: Phase 1
Study type: Interventional

The present study was designed to assess the bioequivalence and pharmacokinetic profiling of a brand generic formulation of darifenacin [Darisec(R)]vs. the innovator [Enablex(R)]in healthy volunteers after a high fat breakfast. The bioequivalence will be evaluated using: - the Area Under the Curve (AUC) and, - the peak plasma concentration (Cmax). Safety will be evaluated recording: - vital signs - adverse events, - laboratory analysis. - EKG and chest XRays. Bioequivalence will be claimed if the drugs comply with local regulatory requirement, eg.: - mean AUCt/AUCr and 90% confidence interval within 0.80-1.25 - mean Cmaxt/Cmaxr and 90% confidence interval within 0.80-1.25.

NCT ID: NCT01039233 Completed - Bioequivalency Clinical Trials

Bioequivalence Study of Bicalutamide 50 mg Tablet and Casodex 50 mg Tablet in Healthy Subjects Under Fasting Conditions

Start date: May 2005
Phase: Phase 1
Study type: Interventional

The objective of this study is to compare the rate and extent of absorption of bicalutamide 50 mg tablet (test) versus Casodex (reference), administered as 1 x 50 mg tablet under fasting conditions

NCT ID: NCT00804440 Completed - Bioequivalency Clinical Trials

Bioequivalence Study Between Two Oral Formulations of Ibuprofen 800 mg Tablets Under Fasting Conditions

Start date: January 2004
Phase: Phase 1
Study type: Interventional

Compare the rate and extent of absorption of two oral formulations of Ibuprofen 800 mg Tablets, administered as a single, one-tablet dose in fasted subjects.

NCT ID: NCT00804401 Completed - Bioequivalency Clinical Trials

Bioequivalence Study Between Two Oral Formulations of Naproxen 500 mg Tablets Under Fasting Conditions

Start date: June 2004
Phase: Phase 1
Study type: Interventional

Compare the rate and extent of absorption of two oral formulations of Naproxen Tablets, administered as a 1 x 500 mg tablet under fasting conditions.

NCT ID: NCT00803946 Completed - Bioequivalency Clinical Trials

Bioequivalence Study Between Two Oral Formulations of Ibuprofen 800 mg Tablets Under Fed Conditions

Start date: November 2003
Phase: Phase 1
Study type: Interventional

Compare the rate and extent of absorption of two oral formulations of Ibuprofen 800 mg Tablets, administered as a 1 x 800 mg tablet, under fed conditions.

NCT ID: NCT00803764 Completed - Bioequivalency Clinical Trials

Bioequivalence Study Between Two Oral Formulations of Naproxen 500 mg Tablets Under Fed Conditions

Start date: June 2004
Phase: Phase 1
Study type: Interventional

Compare the rate and extent of absorption of two oral formulations of Naproxen Tablets, administered as a 1 x 500 mg tablet under fed conditions.